Lenvatinib, immunotherapy, plus liver artery treatment before surgery
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old.
- Your liver cancer (HCC) is confirmed by pathology or accepted diagnosis rules, and you have not had any prior cancer treatment for this liver cancer (like chemo, immunotherapy, targeted therapy, radiation, ablation, or other liver cancer surgery).
- Before surgery, your tumor stage is CNLC IB or IIA, and scans show narrow or no surgical margins, plus blood tests include AFP and PIVKA together above 1600.
- Your health status score is ECOG 0 (fully active) before starting study medicine, and you have enough liver function (Child-Pugh 5–6, liver grade A).
- Your blood counts and organ labs are good enough for surgery (for example, hemoglobin, white cells, platelets, and clotting tests meet the listed limits).
- You can provide a tumor tissue sample (from stored tissue or a new biopsy), and you agree to contraception during the study if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This study tests a combination of two drugs—lenvatinib (a targeted therapy that blocks blood vessel growth) and tislelizumab (an immunotherapy that helps your immune system fight cancer)—in people with advanced liver cancer who also have hepatitis B. The goal is to see if this combination can shrink tumors or slow the cancer's growth, and to find biomarkers (clues in your blood or tissue) that predict who will benefit.
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.